Lithium Dosing Study (LiDS)
Dosing Study of Lithium Orotate for Safety, Tolerability, and Feasibility for Early Stages of Alzheimer's Disease and Related Dementias
LiDS is a dosing study to evaluate the safety, tolerability, and feasibility of daily oral Lithium Orotate (LiO) in aging adults at increased risk for progression of cognitive problems, including Alzheimer's disease and related dementias.
調査の概要
詳細な説明
Lithium orotate (LiO), a compound combining lithium with orotic acid, has shown remarkable neuroprotective effects in preclinical studies by our group - reducing amyloid plaques, lowering brain inflammation, and improving memory. Early human studies suggest that low doses may be safe and potentially beneficial for brain function. Given its affordability, accessibility, and considerably lower side effect profile compared to other lithium-based compounds, LiO warrants further human investigation. However, more information must first be obtained regarding the effects of LiO on the human body, focused on the safety and tolerability of LiO supplementation at various amounts. We propose a 12-week dose-ranging study to evaluate the safety, tolerability, and feasibility of daily oral LiO at different doses of elemental lithium among aging adults across a cognitive spectrum and at risk for progressing to worsening cognitive function, including those with subjective cognitive complaints, mild objective cognitive impairment, or moderate objective cognitive impairment. This represents the most relevant study population in whom to evaluate potential effects of LiO on the human body.
Specific Aims and Objectives
The primary objectives for this dose-ranging trial are to assess:
Safety: Side effects will be tracked via serial REDCap web-based surveys. Blood samples will be collected at baseline and prior to the final study visit (between 8 and 12 weeks during randomized treatment) with thyroid, liver, and kidney function monitoring.
Tolerability: Participants' adherence to assigned study pills and study withdrawal rates will be monitored through regular web-based surveys.
Feasibility: Feasibility will be determined by the successful completion of study procedures, including recruitment and enrollment rates; compliance rates with web-based surveys; participation rates in blood sample collections; change in lithium levels in active vs. placebo groups.
Secondary objectives will involve use of: 1) survey measures of mood, thinking, or functioning, as these represent important additional safety variables (i.e., change in mood or suicidal ideation) and/or common nuisance side effects (i.e., changes in subjective cognition and everyday functioning) that may account for a large share of differences in tolerability of lithium; 2) additional blood biomarkers designed to further capture the effects of the supplement on the human body.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Vivian Anable Eme, B.A.
- 電話番号:8572785338
- メール:vanableeme@mgh.harvard.edu
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114-2696
- Massachusetts General Hospital
-
コンタクト:
- Olivia I Okereke, MD
- 電話番号:617-726-2000
- メール:olivia.okereke@mgh.harvard.edu
-
コンタクト:
- Vivian Anable Eme, BA
- 電話番号:8572785338
- メール:vanableeme@mgh.harvard.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Age 60 years or older at study entry Self-reported ability to read and understand English. As all study surveys have been validated in English, we will limit participation to potential subjects able to read English.
Able to provide informed consent
Must meet criteria for one of the three following cognitive statuses:
Cognitively normal/unimpaired, (TICS-41 score ≥34 with presence of subjective cognitive concerns and without significant hearing impairment
For those without hearing impairment, TICS-41 score 23 to <34 (mild objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of MCI
For those without hearing impairment, TICS-41 score >15 to <23 (moderate objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of mild-stage AD dementia
Must be able and willing to adhere to study procedures
Participants with moderate objective impairment or clinician diagnosis of AD dementia must have a study partner willing to participate in the study with them.
Exclusion Criteria:
Lithium-specific exclusions
History of lithium toxicity, intolerance or hypersensitivity
Use of any lithium formulation in the last six months
History of diagnosed kidney disorders (e.g., chronic kidney disease, dialysis or renal transplant, acute kidney injury within past 6 months)
Unstable thyroid disorders (e.g., medication change in the last 90 days) or history of thyroid surgery, radioactive iodine treatment or active thyroiditis in the last 90 days
Unwilling to forego use of any non-study lithium formulation during the trial
Self-reported major psychiatric and neurological disorders
Bipolar disorder, schizophrenia, or unstable major depression (e.g., recent hospitalization, medication change in the last 90 days).
To optimize participant safety and to ensure that individuals with any degree of suicidal ideation at baseline are not included in the study, the presence of any suicidal ideation at screening will be defined as a score of >0 on PHQ-9 Item 9 or as spontaneously reported during screening. The PHQ-9 will also be administered at 6- and 12-week follow-up time points as a safety monitoring measure. A score of 1 or greater on PHQ-9 Item 9, or spontaneous report of current suicidal ideation at any point during the study, will trigger the suicidality and psychiatric safety procedures detailed under 'Monitoring and Quality Assurance'.
Parkinson disease or other non-AD neurodegenerative disorders (e.g., Huntington's disease)
Self-reported medical conditions
Diagnosis of cardiovascular disease or major cardiovascular procedures in the last 6 months (e.g., cardiac conduction abnormalities, heart attack, stroke, transient ischemic attack, angina pectoris, coronary-artery bypass grafting, percutaneous coronary intervention, cardioversion or ablation)
Diagnosis or treatment of cancer (except non-melanoma skin cancer) in the last 6 months
Concurrent use of anti-amyloid therapies (e.g., Donanemab, Lecanemab)
History of liver disease
Other exclusions
Lab values within the abnormal range (adjusted for age and sex where relevant) for renal function, reflex thyroid tests, and liver function
TICS-41 score ≤15
Score of >50% likelihood of significant hearing impairment according to the Hearing Handicap Inventory-Screening Version (HHIE-S)
Any other serious illness or condition that, in the opinion of the investigators, would preclude safe participation or completion of the study procedures
Concurrent participant in an ongoing clinical trial involving taking a study drug or supplement
Those who report "severe" for items 21-29 on the LiSERS questionnaire
UBACC (the University of California, San Diego Brief Assessment of Capacity to Consent) < 11 indicating inability to provide informed consent. The clinical research coordinator will conduct a comprehension check of the consent form using the UBACC, which will require a perfect score of 11 out of 11 points to indicate capacity to provide informed consent. Prospective participants will be allowed two tries of the UBACC to achieve a score of 11.
Those with hearing impairment who do not report a clinician diagnosis of MCI or AD dementia given concerns for lack of awareness of objective memory decline which could lead to incorrect categorization without use of the TICS-41
Must reside in the states of Connecticut, Rhode Island, Massachusetts, Maine, New Hampshire, or Vermont and be able to have blood draws completed at a New England Quest location in those states.
Failure to complete the baseline blood collection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Placebo pill taken daily for the 12 week study participation period. Placebo pills are in packaging identical to the LiO groups. |
Placebo pill for the Lithium orotate. |
|
アクティブコンパレータ:0.5 mg/day
0.5 mg/day of LiO pills for the 12 week study participation period. |
Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day. |
|
アクティブコンパレータ:1.0 mg/day
1.0 mg/day of LiO pills for the 12 week study participation period. |
Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day. |
|
アクティブコンパレータ:2.5 mg/day
2.5 mg/day of LiO pills for the 12 week study participation period. |
Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day. |
|
アクティブコンパレータ:5.0 mg/day
5.0 mg/day of LiO pills for the 12 week study participation period. |
Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety Monitoring
時間枠:12 weeks
|
Blood samples will be collected at baseline and at a second timepoint prior to the end of the intervention (between 8 and 12 weeks during randomized treatment) for thyroid, liver, and kidney function monitoring. The safety measure is number (%) of participants with abnormal safety events. The safety measures monitored will be Thyroid Stimulating Hormone (TSH with reflex) above or below normal range, Liver Function Tests (LFTs) above normal range, and estimated glomerular filtration rate (EGFR) below 60. A safety event will be considered as an abnormality on any one of these indicators. |
12 weeks
|
|
Tolerability: Study Withdrawal
時間枠:12 weeks
|
Tolerability: Counts and percentages of participants who withdraw from study participation. |
12 weeks
|
|
Tolerability: Adherence to Study Pills
時間枠:12 weeks
|
Tolerability: Participants' adherence to assigned study pills will be monitored through regular web-based surveys and summarized descriptively; proportion of participants achieving predefined adherence thresholds (e.g. taking >=75% of study supplements) will also be reported. |
12 weeks
|
|
Recruitment
時間枠:6 months
|
Recruitment number (count) and percent of planned enrollment. |
6 months
|
|
Compliance: Questionnaire Data
時間枠:12 weeks
|
Study compliance as completion rates (counts and percentages) of the web-based questionnaires. |
12 weeks
|
|
Compliance: Blood Collection
時間枠:12 weeks
|
Counts and percentages of individuals completing the first and final blood collections |
12 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Everyday Cognition(ECoG)
時間枠:12 weeks
|
Survey measure of memory or thinking, using the ECOG, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in subjective cognition) that may be relevant to tolerability of lithium. ECOG items are scored 1-4 points, with worse cognition signified by higher scores. The total score range is 12-48 points. |
12 weeks
|
|
Older Americans Resources and Services-Instrumental Activities of Daily Living (OARS-IADL)
時間枠:12 weeks
|
Survey measure of functioning, using the OARS-IADL, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. A subset of questions from the IADL component of the OARS will be administered via survey. Each item is score 0, 1, or 2, or not applicable/not answered, where higher scores represent greater functional independence and lower scores represents lower functional independence. The total range is 0-12 points. |
12 weeks
|
|
Functional Activities Questionnaire (FAQ)
時間枠:12 weeks
|
Survey measure of functioning, using the FAQ, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. The FAQ features 10 items, each with values between 0 to 3 (or not applicable). The total score range is 0-30 points, with higher scores indicating higher functional dependency or impairment. |
12 weeks
|
|
Patient Health Questionnaire-9 (PHQ-9)
時間枠:12 weeks
|
Survey measure of functioning, using the PHQ-9, as this represents an important safety variable and/or common area of nuisance side effects (changes in mood and/or suicidality) that may be relevant to tolerability of lithium. The PHQ-9 features 9 items, each with values between 0 to 3 (or not applicable). The total score range is 0-27 points, with higher scores indicating higher levels of depressive symptoms. |
12 weeks
|
|
Lithium Side Effects Rating Scale (LiSERS)
時間枠:12 weeks
|
The LiSERS survey is used to measure absence, presence, and/or degree of severity (where applicable/present) to common or known potential side effects of lithium. The LiSERS features 30 items, for which respondents indicate yes or no; if yes, respondents further indicate degree of severity. |
12 weeks
|
|
Additional Blood Biomarkers
時間枠:12 weeks
|
Additional blood biomarkers (Lithium level, inflammatory markers, and ADRD biology markers, specifically pTau217) designed to further capture the effects of the supplement on the human body. These continuous measures of blood biomarkers will be reflected as levels or concentrations of the respective biomarkers. |
12 weeks
|
協力者と研究者
捜査官
- 主任研究者:Olivia I Okereke, PhD、Massachusetts General Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 2026P000799
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Blinded study design; study group data will be analyzed in the aggregate. No Individual Participant Data will be shared.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。